Related Articles
NCI Cancer Research Data Commons: Resources to Share Key Cancer Data
Abstract. Since 2014, the NCI has launched a series of data commons as part of the Cancer Research Data Commons (CRDC) ecosystem housing genomic, proteomic,…
OnlineFirst
This site uses cookies. By continuing to use our website, you are agreeing to our privacy
Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status
AbstractBackground:. OncotypeDx is a prognostic and predictive genomic assay used in early-stage hormone receptor–positive, HER2− (HR+/HER2−) breast cancer. It is used to inform adjuvant chemotherapy…
D3S-001, a KRAS G12C inhibitor with rapid target engagement kinetics, overcomes nucleotide cycling and demonstrates robust preclinical and clinical activities
Abstract. First-generation KRAS G12C inhibitors, such as sotorasib and adagrasib, are limited by the depth and duration of clinical responses. One potential explanation for their…
A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation
Abstract. RAF inhibitors have transformed treatment for BRAF V600-mutant cancer patients, but clinical benefit is limited by adaptive induction of ERK signaling, genetic alterations that…
Warburg Effect Reshapes Tumor Immunogenicity
Abstract. Tumor cells rewire their metabolism to fulfill the demands of highly proliferative cells. This changes cellular metabolism to adapt to fuel and oxygen availability…
Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B Cell Lymphoma
Abstract. Polatuzumab Vedotin (Pola-V) is an antibody-drug conjugate directed to the CD79B subunit of the B cell receptor (BCR). When combined with conventional immunochemotherapy, Pola-V…
NCI Cancer Research Data Commons: Lessons Learned and Future State
Abstract. More than ever, scientific progress in cancer research hinges on our ability to combine datasets and extract meaningful interpretations to better understand diseases and…
Elizabeth McKenna: We have an opening on the Cancer Discovery team! – OncoDaily
Elizabeth McKenna: We have an opening on the Cancer Discovery team! / American Association for Cancer Research, cancer, Cancer Discovery team, Elizabeth
Paolo Tarantino: HER2 is about to change again – OncoDaily
Paolo Tarantino: HER2 is about to change again / AstraZeneca, Breast Cancer, cancer, Cancer Discovery, DESTINY-Breast06 Trial, Enhertu, HER2-low Breast